12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Prochieve regulatory update

Watson said it received a complete response letter from FDA for an NDA for Prochieve vaginal progesterone gel to reduce the risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy. According to...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >